Di Gioacchino Vanessa, Langlois Sylvie, Elliott Alison M
Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Mol Genet Genomic Med. 2019 Apr;7(4):e00572. doi: 10.1002/mgg3.572. Epub 2019 Feb 2.
Just as there is inconsistency with respect to coverage of genomic testing with insurance carriers, there is interprovincial discrepancy in Canada. Consequently, the option of private pay (e.g., self pay) arises, which can lead to inequities in access, particularly when patients may not be aware of this option. There are currently no published data regarding how the Canadian genetics community handles discussions of private pay options with patients. The purpose of this study was to assess the attitudes of genetic healthcare professionals (GHPs: medical geneticists, genetic counselors, and genetic nurses) practicing in Canada toward these discussions.
An online survey was distributed to members of the Canadian College of Medical Geneticists and the Canadian Association of Genetic Counsellors to assess frequencies, rationale, and ethical considerations regarding these conversations. Quantitative data were analyzed using descriptive statistics.
Of 144 respondents, 95% reported discussing private pay and 65% reported working in a clinic without a policy on this issue. There were geographic and practice-specific differences. The most common circumstance for these discussions was when a test was clinically indicated (e.g., but funding was denied) followed by when the patient initiated the conversation. The most frequently discussed tests included: multi-gene panels (73% of respondents), noninvasive prenatal testing (62%), and pre-implantation genetic diagnosis (58%). Although 65% felt it was ethical to discuss private pay, 35% indicated it was "sometimes" ethical.
With the increasing availability of genomic technologies, these findings inform how we practice and demonstrate the need for policy in this area.
正如保险公司在基因检测覆盖范围方面存在不一致一样,加拿大各省之间也存在差异。因此,出现了自费支付(如自付费用)的选择,这可能导致获取医疗服务的不平等,尤其是当患者可能不知道有这种选择时。目前尚无关于加拿大遗传学领域如何与患者讨论自费支付选择的公开数据。本研究的目的是评估在加拿大执业的基因医疗保健专业人员(GHP:医学遗传学家、遗传咨询师和基因护士)对这些讨论的态度。
向加拿大医学遗传学家学院和加拿大遗传咨询师协会的成员发放了一份在线调查问卷,以评估关于这些谈话的频率、理由和伦理考量。使用描述性统计分析定量数据。
在144名受访者中,95%的人报告讨论过自费支付,65%的人报告在没有关于此问题政策的诊所工作。存在地域和实践方面的差异。这些讨论最常见的情况是临床需要进行检测时(如检测申请被拒绝但临床确实需要检测),其次是患者主动提出谈话。讨论最多的检测项目包括:多基因检测组合(73%的受访者)、无创产前检测(62%)和植入前基因诊断(58%)。虽然65%的人认为讨论自费支付是符合伦理的,但35%的人表示这“有时”符合伦理。
随着基因技术的日益普及,这些研究结果为我们的实践提供了参考,并表明了该领域制定政策的必要性。